SecurityLMB / Limbach Holdings, Inc. (53263P105)
President and CEOBacon Charles A. III
IndustryConstruction Special Trade Contractors
Institutional Owners27
Institutional Shares2,585,021 - 34.05%
Common Shares Outstanding7,590,778 shares (as of 2018-06-30)
Institutional Value$ 30,040,000 USD
Related TFSC / 1347 Capital Corp.
LMBH / Limbach Holdings, Inc
LMBHW / Limbach Holdings, Inc

Institutional Stock Ownership and Shareholders

LMB / Limbach Holdings, Inc. Institutional Ownership

Limbach Holdings, Inc. (NASDAQ:LMB) has 27 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 2,585,021 shares. Largest shareholders include State of New Jersey Common Pension Fund D, Dimensional Fund Advisors Lp, Perritt Capital Management Inc, Arbor Wealth Management, LLC, Acuitas Investments, Llc, Legato Capital Management LLC, Argent Capital Management Llc, Vanguard Group Inc, Pacific View Asset Management, Llc, and Bridgeway Capital Management Inc.
Limbach Holdings, Inc. (NASDAQ:LMB) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Prev Value
Current Value
2018-07-30 13F-HR State of New Jersey Common Pension Fund D 644,000 644,000 0.00 7,973 7,612 -4.53
2018-08-14 13F-HR Pacific View Asset Management, Llc 90,860 1,074
2018-08-14 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 2,716 760 -72.02 33 9 -72.73
2018-08-02 13F-HR NJ State Employees Deferred Compensation Plan 43,000 43,000 0.00 532 508 -4.51
2018-08-09 13F-HR Acuitas Investments, Llc 50,060 163,699 227.01 620 1,935 212.10
2018-07-20 13F-HR Steward Partners Investment Advisory, Llc 9,724 11,755 20.89 118 139 17.80
2018-07-17 13F-HR ESSEX INVESTMENT MANAGEMENT CO LLC 18,394 17,851 -2.95 225 211 -6.22
2018-08-14 13F-HR MORGAN STANLEY 0 115 0 1
2018-08-09 13F-HR BlackRock Inc. 9,272 12,970 39.88 113 153 35.40
2018-08-13 13F-HR Advisor Group, Inc. 230 230 0.00 3 3 0.00
2018-08-14 13F-HR VANGUARD GROUP INC 108,444 109,290 0.78 1,342 1,291 -3.80
2018-08-13 13F-HR Renaissance Technologies LLC 13,500 165
2018-08-14 13F-HR PERRITT CAPITAL MANAGEMENT INC 285,050 280,050 -1.75 3,572 3,310 -7.33
2018-08-14 13F-HR UBS Group AG 4,763 5,134 7.79 58 60 3.45
2018-08-14 13F-HR Tower Research Capital LLC (TRC) 8,061 0 -100.00 99 0 -100.00
2018-08-14 13F-HR LPL Financial LLC 42,540 42,540 0.00 520 503 -3.27
2018-04-23 13F-HR SILVER CAPITAL MANAGEMENT LLC 14,236 38,686 171.75 197 189 -4.06
2018-07-30 13F-HR New Jersey Better Educational Savings Trust 46,000 44,000 -4.35 569 520 -8.61
2018-08-14 13F-HR DEUTSCHE BANK AG\ 11,100 13,300 19.82 135 157 16.30
2018-08-14 13F-HR JP Morgan Chase & Co 6,068 72
2018-07-11 13F-HR Legato Capital Management LLC 140,005 140,005 0.00 1,711 1,655 -3.27
2018-08-09 13F-HR ARGENT CAPITAL MANAGEMENT LLC 111,180 111,180 0.00 1,359 1,314 -3.31
2018-07-11 13F-HR Mesirow Financial Investment Management, Inc. 37,093 21,199 -42.85 453 251 -44.59
2018-08-14 13F-HR CWA Asset Management Group, LLC 11,380 10,380 -8.79 139 123 -11.51
2018-08-15 13F-HR Arbor Wealth Management, LLC 213,553 211,808 -0.82 2,695 2,253 -16.40
2018-08-14 13F-HR MACQUARIE GROUP LTD 17,906 2,706 -84.89 219 32 -85.39
2018-08-10 13F-HR DIMENSIONAL FUND ADVISORS LP 458,904 495,935 8.07 5,681 5,862 3.19

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Limbach Holdings, Inc. (LMB) CEO Charlie Bacon on Acquisition of Dunbar Mechanical, Inc. (Transcript)

16h seekingalpha
Limbach Holdings, Inc. (NASDAQ:LMB) Limbach - Dunbar Acquisition Conference Call September 20, 2018 8:30 AM ET (0-1)

Limbach Holdings, Inc 2018 Q2 - Results - Earnings Call Slides

2018-08-16 seekingalpha
The following slide deck was published by Limbach Holdings, Inc in conjunction with their 2018 Q2 earnings call.

Limbach Holdings, Inc. (LMB) CEO Charlie Bacon on Q2 2018 Results - Earnings Call Transcript

2018-08-15 seekingalpha
Greetings and welcome to Limbach Holdings Q2 2018 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions]. As a reminder, this conference is being recorded.

Limbach Holdings, Inc (LMB) CEO Charlie Bacon on Q1 2018 Results - Earnings Call Transcript

2018-05-16 seekingalpha
Limbach Holdings, Inc. (NASDAQ:LMB) Q1 2018 Results Earnings Conference Call May 16, 2018 9:00 AM ET (1-1)

Limbach Holdings, Inc 2018 Q1 - Results - Earnings Call Slides

2018-05-16 seekingalpha
The following slide deck was published by Limbach Holdings, Inc in conjunction with their 2018 Q1 earnings call. (1-0)

CUSIP: 53263P105